Johnson & Johnson's Janssen Pharmaceuticals agreed to team up with researchers from the University of Leuven in Belgium and the Wellcome Trust charity to develop treatments for dengue fever. The collaboration will focus on a series of compounds that have been shown to block dengue virus replication. The deal includes upfront payment as well as potential milestone fees and royalties.

Full Story:

Related Summaries